Drug Development Pipeline

Our Mission: To translate advances in modern cancer science into new medicines that improve treatment options for dogs with cancer.

Our Vision: A future where dogs with cancer can benefit from the same advances transforming modern cancer medicine.

CaniVax develops new cancer medicines by translating advances in modern cancer science into treatments designed specifically for dogs.

We focus on areas where the biology is well understood and there is a clear unmet clinical need, then use modern drug development, vaccine technologies and AI tools to build and refine new therapies.

Our strategy combines near-term product development with scalable platforms that can generate additional medicines across multiple canine cancers.

Development Stages

  1. 1 Microscope icon representing discovery and product design

    Discovery & Product Design

    Identify biological targets and design candidate product.

  2. 2 Immune cell icon representing preclinical validation

    Preclinical Validation

    Evaluate safety, biological activity and product performance.

  3. 3 Vial icon representing translational development

    Translational Development

    Optimise manufacturing, formulation and quality.

  4. 4 Veterinary clinic icon representing clinical development

    Clinical Development

    Clinical studies in dogs to assess safety & efficacy.

  5. 5 Approved certificate icon representing regulatory approval

    Regulatory & Marketing Approval

    Seek regulatory approval and expand access to canine patients.

CaniVax Pipeline

  • Complete
  • In progress
  • Planned
1Discovery & Product Design
2Preclinical Validation
3Translational Development
4Clinical Development
5Regulatory & Marketing Approval
Blue cancer cells icon CaniVive™ Lymphoma
Oral cancer drug targeting lymphoma and other cancers
Green cancer cells icon CaniMel™ Melanoma
Precision cancer vaccine designed against melanoma.
Red cancer cells icon CaniMCT™ Mast Cell Tumour
Precision cancer vaccine designed against mast cell tumours.
Purple cancer cells icon CaniOST™ Osteosarcoma
Precision cancer vaccine designed against osteosarcoma.

Bringing Modern Cancer Science to Dogs

We believe dogs with cancer deserve to benefit from the same scientific progress transforming modern oncology.

Disclaimer: CaniVax programmes are investigational and not yet approved for use outside of clinical studies. Timelines, development plans, and programme descriptions reflect our current expectations, beliefs, and objectives, and are subject to change. Future development, regulatory progress, and commercial outcomes cannot be guaranteed.

Hands, vet and dog at clinic with consulting, care and stroke for health, development and growth with wellness. People, doctor and golden retriever pet with check, exam and help at animal hospital
Oxford

Contact Us

Dog owners and veterinary professionals can use this form to learn more about CaniVax medicines in development, including potential clinical access and participation in clinical trials.

Tell us briefly about your dog, patient or clinical interest, and we will contact you to discuss the relevant programme and whether an appropriate route may be available.

Submitting this form does not guarantee access to treatment.

Register your interest below:

Name(Required)

Photo credit © Adrian Baughan - Oxford Dog Photography.